Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study

NCT01949870 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped change in the development strategy

Conditions

Inoperable Locally Advanced or Metastatic Biliary Tract Cancer

Interventions

DRUG: Cisplatin
DRUG: Gemcitabine
DRUG: Selumetinib

Sponsor

AstraZeneca